AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27322592 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic counseling (GC) within 1 month of report viewing
Number of subjects: 199
Study 27322592 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to counseling 3 months post-report viewing
Number of subjects: 199
Study 25244665 — intervention group
Group type: EXPERIMENTAL
Intervention: Isonicotinic acid hydrazide (INH) 900 mg
Number of subjects: 150
Study 25244665 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol 25 μg
Number of subjects: 150
Study 23040783 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic imipenem cilastatin sodium 1.0 g intravenous drip, every 6-8 hours for 7-14 days
Number of subjects: 68
Study 23040783 — intervention group
Group type: COMPARATOR
Intervention: Imported injection imipenem cilastatin sodium 1.0 g intravenous drip, every 6-8 hours for 7-14 days
Number of subjects: 68
Study 19861362 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 80
Study 19861362 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 17640599 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured walking regimen
Number of subjects: 100
Study 17640599 — intervention group
Group type: COMPARATOR
Intervention: Control group with no formal exercise program
Number of subjects: 100
Study 16055833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 270
Study 12391945 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive technology given to patients treated in a stroke unit
Number of subjects: 249
Study 12391945 — intervention group
Group type: COMPARATOR
Intervention: Assistive technology given to patients treated in a general medical ward
Number of subjects: 249
Study 10623356 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte filtration during cardiopulmonary bypass
Number of subjects: 31
Study 10623356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no filtration)
Number of subjects: 31
Study 7541190 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (0.05%) ointment
Number of subjects: 6
Study 7541190 — intervention group
Group type: COMPARATOR
Intervention: Base ointment
Number of subjects: 6
Study 2132086 — intervention group
Group type: EXPERIMENTAL
Intervention: K-Mg aspartate
Number of subjects: 100
Study 2132086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg aspartate
Number of subjects: 100
Study 2132086 — intervention group
Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 100
Study 499960 — intervention group
Group type: EXPERIMENTAL
Intervention: Card-Dusodril 1/8 (0.5 mg digoxin)
Number of subjects: 14
Study 499960 — intervention group
Group type: EXPERIMENTAL
Intervention: Card-Dusodril 1/4 (1 mg digoxin)
Number of subjects: 14
Study 499960 — intervention group
Group type: COMPARATOR
Intervention: Intravenously applied digoxin (control)
Number of subjects: 14
Study 499960 — intervention group
Group type: EXPERIMENTAL
Intervention: Card-Dusodril 1/8 and 1/4
Number of subjects: 14
Study 31164071 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 739
Study 31164071 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 739
Study 28605527 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (2 mA, 30 minutes for 10 consecutive days)
Number of subjects: 40
Study 28605527 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 40
Study 26696112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2mg/kg)
Number of subjects: 20
Study 26696112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual midazolam (0.2mg/kg)
Number of subjects: 20
Study 24779025 — intervention group
Group type: EXPERIMENTAL
Intervention: Silorane-based composite (Filtek P90/P90 System Adhesive)
Number of subjects: 78
Study 24779025 — intervention group
Group type: COMPARATOR
Intervention: Methacrylate-based resin composite (Quixfil/Prime &Bond NT)
Number of subjects: 78
Study 22469098 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2066 13 mg
Number of subjects: 32
Study 22469098 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2066 2 mg
Number of subjects: 32
Study 22469098 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD2066 6 mg
Number of subjects: 32
Study 22469098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 21032979 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial myofunctional therapy (OMT)
Number of subjects: 30
Study 21032979 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint (OS)
Number of subjects: 30
Study 21032979 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (SC)
Number of subjects: 30
Study 21032979 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic group (AC)
Number of subjects: 30
Study 18591167 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise intervention
Number of subjects: 20
Study 18591167 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 16091788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic conditioning during the second and third trimesters
Number of subjects: 28
Study 16091788 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 28
Study 11808830 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (175 mg)
Number of subjects: 24
Study 11808830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune (300 mg)
Number of subjects: 24
Study 11808830 — intervention group
Group type: COMPARATOR
Intervention: Cmax of cyclosporine
Number of subjects: 24
Study 10073243 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg droperidol
Number of subjects: 184
Study 10073243 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol
Number of subjects: 184
Study 10073243 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg droperidol
Number of subjects: 184
Study 10073243 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 184
Study 7750190 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) at an initial dosage of 2 IU/m2 body surface/day, increased if height velocity increment was less than 2 cm/year
Number of subjects: 55
Study 7750190 — intervention group
Group type: COMPARATOR
Intervention: untreated control group with ISS
Number of subjects: 55
Study 7750190 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment in isolated GH deficiency (GHD) group
Number of subjects: 55
Study 7750190 — intervention group
Group type: EXPERIMENTAL
Intervention: ISS group
Number of subjects: 55
Study 7750190 — intervention group
Group type: COMPARATOR
Intervention: untreated controls
Number of subjects: 55
Study 2115156 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled disodium cromoglycate (DSCG) 40 mg
Number of subjects: 12
Study 2115156 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol 200 micrograms
Number of subjects: 12
Study 2115156 — intervention group
Group type: COMPARATOR
Intervention: No premedication (test A)
Number of subjects: 12
Study 6988171 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trimebutine 3-times daily for 3 days
Number of subjects: 0
Study 6988171 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg trimebutine 3-times daily for 2 weeks
Number of subjects: 0
Study 6988171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6988171 — intervention group
Group type: COMPARATOR
Intervention: 100 mg mebeverine 4-times daily
Number of subjects: 0
Study 31638682 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n=75)
Number of subjects: 146
Study 31638682 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=71)
Number of subjects: 146
Study 31638682 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine vs Placebo
Number of subjects: 146
Study 29132733 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply (energy, amino acids, lipids, long‐chain polyunsaturated fatty acids, vitamin A)
Number of subjects: 50
Study 29132733 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply
Number of subjects: 50
Study 29132733 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrient supply (control group)
Number of subjects: 50
Study 29132733 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard nutrient supply)
Number of subjects: 50
Study 26047808 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Bipolar Parenting Intervention (IBPI)
Number of subjects: 0
Study 26047808 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 23622019 — intervention group
Group type: EXPERIMENTAL
Intervention: Head of bed elevation (HBE) at 45°
Number of subjects: 200
Study 23622019 — intervention group
Group type: COMPARATOR
Intervention: Pressure-controlled ventilation
Number of subjects: 200
Study 20589679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydroxyurea and imatinib
Number of subjects: 101
Study 20589679 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea monotherapy
Number of subjects: 101
Study 20589679 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGFRα positive glioblastoma
Number of subjects: 101
Study 20589679 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGFRα expression
Number of subjects: 101
Study 20589679 — intervention group
Group type: EXPERIMENTAL
Intervention: PDGFRα phosphorylation
Number of subjects: 101
Study 19526158 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion (RP‐E)
Number of subjects: 40
Study 19526158 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion (RP)
Number of subjects: 40
Study 17920639 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 80
Study 17920639 — intervention group
Group type: COMPARATOR
Intervention: Control substance
Number of subjects: 80
Study 16125218 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking, resistance training
Number of subjects: 90
Study 16125218 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet only)
Number of subjects: 90
Study 16125218 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (walking, resistance training, control)
Number of subjects: 90
Study 12010224 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Crohn's disease (CD)
Number of subjects: 57
Study 12010224 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a functioning colon
Number of subjects: 57
Study 10450621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral bibliotherapy (BT)
Number of subjects: 54
Study 10450621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral bibliotherapy (BT) with weekly phone consultations
Number of subjects: 54
Study 10450621 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (WL)
Number of subjects: 54
Study 8563376 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician's Workstation (PWS)
Number of subjects: 0
Study 2528817 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based interview system
Number of subjects: 50
Study 2528817 — intervention group
Group type: COMPARATOR
Intervention: Conventional clerking by a doctor
Number of subjects: 50
Study 321176 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40 mg/day
Number of subjects: 23
Study 321176 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg/day + Triamterene 50 mg/day
Number of subjects: 23
Study 321176 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg/day + Triamterene 100 mg/day
Number of subjects: 23
Study 30977721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with overweight child and positive communication tone
Number of subjects: 233
Study 30977721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette with overweight child
Number of subjects: 233
Study 31083706 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBHI) scheme
Number of subjects: 528
Study 31083706 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate knowledge of CBHI benefit packages
Number of subjects: 528
Study 31083706 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of health facility visit
Number of subjects: 528
Study 31083706 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory service provision
Number of subjects: 528
Study 31083706 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of enrollment
Number of subjects: 528
Study 27371341 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50 (LM50)
Number of subjects: 156
Study 27371341 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro mix 25 (LM25)
Number of subjects: 156
Study 25515848 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person narrative message with experiential information processing
Number of subjects: 138
Study 25515848 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person narrative message with rational information processing
Number of subjects: 138
Study 25515848 — intervention group
Group type: COMPARATOR
Intervention: Statistical message with experiential information processing
Number of subjects: 138
Study 25515848 — intervention group
Group type: COMPARATOR
Intervention: Statistical message with rational information processing
Number of subjects: 138
Study 22744960 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening questions printed on prescreener forms (PSF)
Number of subjects: 0
Study 22744960 — intervention group
Group type: EXPERIMENTAL
Intervention: Just in time (JIT) printed materials to aid physicians
Number of subjects: 0
Study 22744960 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians reminded to screen on printed worksheets)
Number of subjects: 0
Study 20739147 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy combined with hypocaloric parenteral nutrition (HPN) including recombinant human growth hormone, octreotide, and systemic insulin
Number of subjects: 100
Study 20739147 — intervention group
Group type: COMPARATOR
Intervention: Standard total parenteral nutrition and systemic insulin
Number of subjects: 100
Study 19216734 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cultured osteoblast injection
Number of subjects: 64
Study 19216734 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 64
Study 17502045 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 0
Study 15130633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 intraocular lens (IOL)
Number of subjects: 30
Study 15130633 — intervention group
Group type: COMPARATOR
Intervention: Sensar OptiEdge AR40e IOL
Number of subjects: 30
Study 11574374 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg intrathecal morphine (MS)
Number of subjects: 66
Study 11574374 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mL of 0.9% saline (normal saline; NS)
Number of subjects: 66
Study 9270509 — intervention group
Group type: EXPERIMENTAL
Intervention: Butenafine
Number of subjects: 78
Study 9270509 — intervention group
Group type: COMPARATOR
Intervention: Cream vehicle (control)
Number of subjects: 78
Study 7930255 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 7930255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2465687 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal instruction
Number of subjects: 28
Study 2465687 — intervention group
Group type: COMPARATOR
Intervention: Videocassette instruction
Number of subjects: 28
Study 2465687 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 30550338 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory rehearsal
Number of subjects: 0
Study 30550338 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional refreshing
Number of subjects: 0
Study 28885479 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% subcutaneous immunoglobulin (SCIG)
Number of subjects: 15
Study 28885479 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training and support for self-infusion
Number of subjects: 15
Study 25695181 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of hand washing and once-weekly application of chlorhexidine-based body wash
Number of subjects: 0
Study 25695181 — intervention group
Group type: EXPERIMENTAL
Intervention: Incrementally increasing education- and hygiene-based measures
Number of subjects: 0
Study 25695181 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23633524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 17
Study 23633524 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 17
Study 22099273 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mEq per day of oral potassium-sodium citrate (27 mEq three times a day)
Number of subjects: 76
Study 22099273 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated group)
Number of subjects: 76
Study 18337330 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant treatment
Number of subjects: 257
Study 18337330 — intervention group
Group type: COMPARATOR
Intervention: Control households (no treatment)
Number of subjects: 257
Study 18337330 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up on purchase and use of flocculant-disinfectant
Number of subjects: 257
Study 18337330 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized to intervention group
Number of subjects: 257
Study 18337330 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spending on laundry soap, toothpaste, and hand soap
Number of subjects: 257
Study 17145742 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 4360
Study 17145742 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 4360
Study 17145742 — intervention group
Group type: EXPERIMENTAL
Intervention: glyburide
Number of subjects: 4360
Study 12689805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention (two 45‐min counseling sessions plus two brief follow‐up telephone contacts)
Number of subjects: 616
Study 12689805 — intervention group
Group type: COMPARATOR
Intervention: Control intervention unrelated to diet
Number of subjects: 616
Study 10773056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled random-donor platelets (PP) transfusions during Study Period B (≤3-day-old PPs)
Number of subjects: 0
Study 10773056 — intervention group
Group type: COMPARATOR
Intervention: Pooled random-donor platelets (PP) transfusions during Study Period A (older PPs)
Number of subjects: 0
Study 10773056 — intervention group
Group type: COMPARATOR
Intervention: Single-donor apheresis platelets (SDP) transfusions during Study Period B
Number of subjects: 0
Study 9003855 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine administered by twice‐daily subcutaneous injections
Number of subjects: 20
Study 9003855 — intervention group
Group type: COMPARATOR
Intervention: Conventional administration by prolonged subcutaneous infusion
Number of subjects: 20
Study 9003855 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daily dose administered as a single injection
Number of subjects: 20
Study 9003855 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of deferoxamine
Number of subjects: 20
Study 1488663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (colloidal bismuth subcitrate and ampicillin)
Number of subjects: 48
Study 1488663 — intervention group
Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (CBS) therapy
Number of subjects: 48
Study 1488663 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin therapy
Number of subjects: 48
Study 3698065 — intervention group
Group type: EXPERIMENTAL
Intervention: One 500-mg clotrimazole vaginal tablet for one day
Number of subjects: 42
Study 3698065 — intervention group
Group type: COMPARATOR
Intervention: Two 100-mg clotrimazole vaginal tablets daily for three days
Number of subjects: 42
Study 3698065 — intervention group
Group type: COMPARATOR
Intervention: Three-day treatment group
Number of subjects: 42
Study 29878043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose (25% wt:vol, ∼1400 mOsmol/L)
Number of subjects: 12
Study 29878043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal sucralose (4 mmol/L, ∼300 mOsmol/L)
Number of subjects: 12
Study 29878043 — intervention group
Group type: COMPARATOR
Intervention: Intraduodenal saline (0.9% wt:vol, ∼300 mOsmol/L)
Number of subjects: 12
Study 27281699 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation (2.9 g/d)
Number of subjects: 20
Study 27281699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24370819 — intervention group
Group type: EXPERIMENTAL
Intervention: Active motor rehabilitation treatment based on voluntary exercises including task-oriented exercises.
Number of subjects: 30
Study 24370819 — intervention group
Group type: COMPARATOR
Intervention: Passive mobilization of the shoulder, elbow, wrist and fingers (Control group).
Number of subjects: 30
Study 24370819 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Active and Control).
Number of subjects: 30
Study 22729935 — intervention group
Group type: EXPERIMENTAL
Intervention: Construction laborers
Number of subjects: 1555
Study 22729935 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor freight workers
Number of subjects: 1555
Study 20723644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 476
Study 20723644 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (5 g IV for 1 hour, followed by ibutilide and another 5 g for 2 additional hours)
Number of subjects: 476
Study 19004414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of MDMA (50-75 mg)
Number of subjects: 6
Study 15879361 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1700 mg daily) for 6 months
Number of subjects: 20
Study 15879361 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal women of similar age and BMI), N=20
Number of subjects: 20
Study 12569213 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (4 sets of 2-min contractions at 30% maximum voluntary contraction, 3 times per week for 10 weeks)
Number of subjects: 17